Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 12/20 | 0.61 |
| ▸ | MCHR2 | Q969V1 | 2/20 | 0.60 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.51 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.51 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.51 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | DRD4 | P21917 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4246648 | 0.89 | CHRNA7 (0.60) | MCHR1MCHR2DUSP3PTPN5PTPN11 | |
| SCHEMBL4245241 | 0.88 | MCHR1 (0.55) | MCHR1MCHR2HTR3ACHRNA7KCNH2 | |
| SCHEMBL4244089 | 0.87 | MCHR1 (0.60) | MCHR1MCHR2DUSP3PTPN5PTPN11 | |
| SCHEMBL4245219 | 0.85 | HTR3A (0.57) | HTR3ACHRNA7KCNH2 | |
| SCHEMBL4246865 | 0.83 | MCHR1 (0.57) | MCHR1MCHR2DUSP3PTPN5PTPN11 | |
| SCHEMBL4389852 | 0.81 | MCHR1 (0.56) | MCHR1CHRNA7KCNH2 | |
| SCHEMBL4392484 | 0.81 | ALDH1A1 (0.62) | MCHR1MCHR2CHRNA7KCNH2 | |
| SCHEMBL4397732 | 0.79 | CHRNA7 (0.61) | MCHR1MCHR2CHRNA7KCNH2 | |
| SCHEMBL4246643 | 0.78 | CHRNA7 (0.58) | MCHR1MCHR2CHRNA7KCNH2MET | |
| SCHEMBL6109418 | 0.77 | MCHR1 (0.93) | MCHR1MCHR2HTR3ADRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105217-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| US-20090105217-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| US-20090105217-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| WO-2007138033-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105217-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA2 | MCHR1 356/4885MCHR2 379/4885DUSP3 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.